Bio-Path Holdings Reports Second Quarter 2015 Operational and Financial Results

BPTH Earnings_2Q15

Bio-Path Holdings Announces “At the Market” Offering with Cantor Fitzgerald

ATM_with_Cantor_20150625

Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results

Bpth1Q2015Results

Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia

ODD_for_AML20150428

Letter to Shareholder from President and CEO

BPTH_sh_ letter20150424

Bio-Path Holdings’ Drug Delivery Technology to be Featured in a Presentation at IBC’s 17th Annual TIDES Oligoneucleotide and Peptide Therapeutics Conference

PR_TIDES_Conf_pres

Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results

Letter to Shareholder from President and CEO

Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients

Phase_II_starts

Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery”

PeerExpertOpinion20150107